India, April 6 -- ABL Bio Inc. announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier or BBB shuttle platform, Grabody-B.
The agreement focuses on creating various programs targeting innovative pathways through different therapeutic approaches. These include antibodies, polynucleotides, and oligonucleotides like siRNA and ASOs. The goal is to meet the critical medical needs of patients living with neurodegenerative diseases.
The blood-brain barrier (BBB) serves as a protective barrier that restricts the entry of harmful substances and agents into the brain and is considered a significant obstacle in the development of treatments for neurol...